Precision Oncology: Accelerated Target and Drug Discovery
Systems Biology Ireland (SBI) specialises in cellular signal transduction investigation with a particular focus on development of new treatment strategies in cancer. The centre has expertise in
- Drug target and biomarker discovery
- Patient stratification and sub-population characterisation
- Combination therapy prediction and screening
- Drug library screening
- Protein-Protein interaction profiling
The experimental approach of the group combines traditional biological experimentation with computational modelling and simulation. This combined approach allows important nodes in signalling networks to be identified quickly and at a lower cost than might otherwise be possible.
Since 2009, SBI investigators have published more than 200 research and review articles in journals with an average impact factor of seven. Over this same period, the group has identified and validated numerous new and promising therapeutic targets for treatment of breast cancer, melanoma, neuroblastoma, and colorectal cancer. The group has developed a sizable portfolio of related potential therapeutic interventions.
Partnering and Co-development
Commercialisation of basic research is a key goal of SBI. We recognise that partnering with start-ups or larger organisations is a very effective way of moving pre-clinical projects through important phases of commercial development and validation. Some of the current projects underway within the group are summarised in projects. Please sign up for our newsletter if you are interested in being notified of new partnering opportunities or upcoming events.
Our researchers are experts in generation, analysis and interpretation of ‘omics’ data (metabolomics, proteomics, transcriptomics, genomics) and integration of this information into predictive computational models. If your organisation generates large amounts of experimental data or if you are interested in leveraging publically available ‘omics’ data to complement your core business activities then our team can help. Individual researchers or teams are available to assist with ‘omics’ data generation, integration of existing warehoused data into predictive models or to advise on infrastructural requirements for planned ‘omics’ initiatives.
Companies interested in accessing specific hardware or expertise may do so through our core facilities portal. The UCD Conway core technologies programme includes a wide range of analysis hardware and is operated and maintained by dedicated technology managers. The suite of genomics, proteomics, flow cytometry and imaging technologies enables a wide range of data driven experimentation.
All hardware is managed by highly skilled researchers who work locally and externally with partners in all areas of experimentation including design, experiment execution and downstream data analysis. If you are interested in learning more about core technology capabilities at SBI, our technology managers are available to answer any research questions that you might have. Current technologies include:
Laboratory Facilities and Shared Workspaces
The UCD Conway Institute and SBI offer fully serviced laboratory and office space to start-ups and SMEs interested in locating at the university. Shared facilities are available at very competitive rates and include priority access to all core facilities and services at the Institute.